Cytoreductive nephrectomy (CN) predicts improved survival among patients with metastatic renal cell carcinoma (RCC) and synchronous metastases who have received first-line treatment with sunitinib, indicate study findings.

Not only did patients who underwent CN have an approximate 50% reduction in the risk of death compared with their counterparts who did not undergo the procedure, CN remained significantly independently predictive of prolonged survival in multivariate analysis.

However, Aristotle Bamias (University of Athens, Greece) and colleagues warn that the exact role of CN and the best method for selecting subgroups of patients most likely to gain a survival benefit still need to be clarified by the results of ongoing randomised clinical trials.

Continue Reading

READ FULL ARTICLE Curated publisher From News Medical